ABBOTT PARK, Ill., Feb. 16, 2024 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 55 cents per share.
This marks the 401st consecutive quarterly dividend to be paid by Abbott since 1924. The cash dividend is payable May 15, 2024, to shareholders of record at the close of business on April 15, 2024.
Abbott has increased its dividend payout for 52 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that have increased dividends annually for at least 25 consecutive years.
About Abbott: Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 114,000 colleagues serve people in more than 160 countries.
Obsidian Therapeutics, Inc., a clinical-stage biotechnology company pioneering engineered cell and gene therapies, today announced the appointment of Dana Alexander as Chief Technical Officer.
"Dana has over two decades of operational expertise...
Lindus Health, an anti-CRO running radically faster, more reliable clinical trials for life science pioneers, is announcing the appointment of Dr. Tim Garnett, pharma industry leader and former Chief Medical Officer at Eli Lilly, to their advisory...
Testmate Health, a pioneer in at-home testing solutions, has secured USD $6 million in seed funding to develop an industry-first, low-cost, over-the-counter , self-test for sexually transmitted infections (STI), starting with chlamydia and...
4C Medical Technologies, Inc. ("4C Medical"), a medical device company dedicated to advancing minimally invasive therapies for structural heart disease, has been granted Breakthrough Device designation by the U.S. Food and Drug Administration (FDA)...
Astria Therapeutics, Inc. , a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that it will present information on the preclinical profile of STAR-0310 at the upcoming...
Immunome, Inc. , a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Clay Siegall, PhD, President and Chief Executive Officer, will present at the 2024 Bank of America...
